Treatment Strategy for Non-Responders to PDE5 Inhibitors
The World Journal of Men's Health
;
: 31-35, 2013.
Artículo
en Inglés
| WPRIM
| ID: wpr-186056
ABSTRACT
Currently, phosphodiesterase type 5 (PDE5) inhibitors are the initial treatment option for erectile dysfunction. The reported efficacy of PDE5 inhibitors is about 70%, although it is significantly lower in difficult-to-treat subpopulations. Treatment failures might be due to the severity of the underlying pathophysiology, improper use of medication, unrealistic patient expectations, difficult relationship dynamics, severe performance anxiety, and other psychological problems. Physicians must address these issues to identify true treatment failures attributable to the drugs. This article discusses factors that might affect the response to PDE5 inhibitors and develops a strategy to maximize the overall efficacy of PDE5 inhibitors in initial non-responders to PDE5 inhibitors.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Piperazinas
/
Purinas
/
Sulfonas
/
Triazinas
/
Carbolinas
/
Insuficiencia del Tratamiento
/
Inhibidores de Fosfodiesterasa 5
/
Ansiedad de Desempeño
/
Citrato de Sildenafil
/
Diclorhidrato de Vardenafil
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
The World Journal of Men's Health
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS